Literature DB >> 7936238

Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990.

J M Gorell1, C C Johnson, B A Rybicki.   

Abstract

Using data from death certificates, we compared underlying causes of death for two populations of Michigan decedents: (1) persons 40 years of age and older for whom Parkinson's disease (PD) was listed as a contributing cause of death and who died in the years 1970 through 1989, and (2) all persons in Michigan over 40 years of age who died in 1970, 1980, or 1990. PD decedents were approximately 1.5 times more likely to die from cerebrovascular disease and three to four times more likely to die from pneumonia/influenza, but they had just 29% of the expected number of deaths due to cancer. These associations were maintained irrespective of gender or race. PD decedents had diabetes mellitus and heart diseases as frequently as decedents in the general population, but liver diseases were less frequent among PD decedents. These trends held throughout the 21-year study period. When we stratified cancers by whether they are known to be (1) highly related, (2) moderately related, or (3) weakly related or unrelated to smoking, there were still 2.5 times fewer cancers unrelated or weakly related to smoking among PD decedents than among decedents in the general population. We believe that the greater frequency of cerebrovascular disease in PD decedents may be due to a detection bias, since PD patients are more likely to be seen by neurologists, who are more apt to diagnose and document diseases of the nervous system. Pneumonia/influenza is more common among PD patients because of their relative immobility near the end of life.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7936238     DOI: 10.1212/wnl.44.10.1865

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  44 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

3.  Parkinson's disease and cerebrovascular disease: is there a link? A neurosonological case-control study.

Authors:  Sandro Zambito Marsala; Manuela Gioulis; Michele Pistacchi; Cecilia Lo Cascio
Journal:  Neurol Sci       Date:  2016-07-09       Impact factor: 3.307

4.  Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial.

Authors:  M S Troche; M S Okun; J C Rosenbek; N Musson; H H Fernandez; R Rodriguez; J Romrell; T Pitts; K M Wheeler-Hegland; C M Sapienza
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

5.  Swallowing outcomes following unilateral STN vs. GPi surgery: a retrospective analysis.

Authors:  Michelle S Troche; Alexandra E Brandimore; Kelly D Foote; Takashi Morishita; Dennis Chen; Karen W Hegland; Michael S Okun
Journal:  Dysphagia       Date:  2014-03-21       Impact factor: 3.438

Review 6.  The neuropathology of chronic traumatic encephalopathy.

Authors:  Ann C McKee; Thor D Stein; Patrick T Kiernan; Victor E Alvarez
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

7.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

8.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

9.  Detraining outcomes with expiratory muscle strength training in Parkinson disease.

Authors:  Michelle S Troche; John C Rosenbek; Michael S Okun; Christine M Sapienza
Journal:  J Rehabil Res Dev       Date:  2014

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.